Dr Marc Pellegrini

Dr Marc Pellegrini

left-column

headshot-wrapper

Dr Marc Pellegrini in the lab

the-headshot-content

Dr
Marc
Pellegrini

BSc MBBS PhD Melbourne FRACP

Joint Division Head

My laboratory focuses on understanding why some infections are not cleared from our body, but persist within cells. These are called chronic infections. HIV, hepatitis B virus (HBV) and tuberculosis are three globally significant chronic infections. Together they cause more than five million deaths globally each year. 
There is no cure for HIV or HBV. Antibiotic resistance is increasing in the bacteria causing tuberculosis. New therapies that control or cure chronic infections are urgently required. 

Our research is revealing how microbes sabotage the processes that normally eradicate infections. Our goal is to discover and deliver new therapies that can promote clearance of chronic infections.

Research interest

Our research is focused on understanding host-pathogen interactions. We are particularly interested in defining the impact that intracellular pathogens have on host cell signalling, cell survival and cell death molecular pathways. The aim of our work is to manipulate host cell signalling pathways to preferentially promote clearance of infected cells and thereby eradicate chronic infections. 

Our work spans the broad areas of basic, translational, pre-clinical, clinical and ‘in the field’ research. Our goal is to develop novel therapeutics and interventions that mitigate morbidity and mortality associated with chronic human infections including HIV, HBV, tuberculosis and human herpes virus.

 

 

Marc Pellegrini and Greg Ebert

Our scientists have found a potential cure for hepatitis B virus infections, with a promising new treatment proving 100 per cent successful in preclinical models.

Dr Marc Pellegrini in the lab

Our research has led to a potential new treatment that kills cells infected with hepatitis B.

Dr Marc Pellegrini at the institute

Dr Marc Pellegrini interviewed on 3RRRFM radio about superbugs.